Last Price
13.06
Today's Change
-0.02 (0.15%)
Day's Change
12.90 - 13.12
Trading Volume
42,550
Market Cap
653 Million
Shares Outstanding
50 Million
Avg Volume
90,541
Avg Price (50 Days)
13.96
Avg Price (200 Days)
14.59
PE Ratio
18.66
EPS
0.70
Earnings Announcement
20-Feb-2025
Previous Close
13.08
Open
13.08
Day's Range
12.9 - 13.12
Year Range
12.8 - 18.2
Trading Volume
42,550
1 Day Change
-0.15%
5 Day Change
-3.19%
1 Month Change
-9.93%
3 Month Change
-3.26%
6 Month Change
-16.12%
Ytd Change
-19.68%
1 Year Change
-24.55%
3 Year Change
-55.56%
5 Year Change
-54.65%
10 Year Change
195.48%
Max Change
326.80%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Heavenly PUNTER Lynas Boleh
Potential 20 baggers
2019-06-11 14:49